Issue 92

The Power of Bipartisan Support

Last week, the U.S Department of Health and Human Services revealed the government expects both MDMA and psilocybin to be regulated in two years.

A letter served as a clear indication that officials are preparing for the approval of psychedelic healthcare, with The Substance Abuse and Mental Health Services Administration noting psychedelic medicines could be vital in addressing the mental health crisis.

A federal taskforce was proposed to oversee the roll-out of psychedelic healthcare, exploring challenges to its commercialisation to promote accessibility and adoption.

CANADIAN GOVERNMENT SUED OVER PSILOCYBIN ACCESS

The Canadian government is being sued for restricting patient access to psilocybin. A similar trial led to the first cannabis laws.

THE APPLICATION OF PSYCHEDELIC MEDICINES IN PSYCHIATRY

BBC Science Focus explores the therapeutic use of psychedelic medicines and their mechanisms of action.

BUSINESS AND INVESTMENT

COMPASS launches Phase II study for anorexia.

Braxia Scientific reports financial results.

Filament Health to participate in Project Solace.

The efficacy of MDMA in couples therapy.

A rise in recreational psilocybin use.

The use of ketamine for chronic pain.

The Psychedelics as Medicine Report provides market insights from industry experts.

With over 60,000 downloads, the flagship publication contains proprietary data for regulators, researchers and investors to make informed decisions.

Previous partners include atai Life Sciences, COMPASS Pathways, Cybin and Filament Health.

To be included in the fourth edition and to discuss future events, please contact grace@psych.global

CONTACT FORM

SCIENCE AND RESEARCH

How serotonin receptor variants affect patient response.

Canadian government funds psychedelic research.

One in four US citizens has tried a psychedelic medicine.

REGULATION AND LEGISLATION

San Francisco lawmakers file decriminalisation measure.

Psilocybin prescriptions in Canada.